We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+8.66%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$16.6M
AUM Growth
-$7.53M
Cap. Flow
-$9.71M
Cap. Flow %
-58.34%
Top 10 Hldgs %
98.81%
Holding
16
New
4
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$287K
2
CBIO
Crescent Biopharma
CBIO
+$55.5K
3
CRDF icon
Cardiff Oncology
CRDF
+$41.5K
4
IKT icon
Inhibikase Therapeutics
IKT
+$40.9K

Top Sells

Rank Stock Value
1
XERS icon
Xeris Biopharma Holdings
XERS
+$9.97M
2
ABVX
Abivax
ABVX
+$131K
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$25.9K
4
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$8.31K

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Financials 3.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XERS icon
1
Xeris Biopharma Holdings
XERS
$1.52B
$6.83M 41.06%
2,015,157
-3,098,191
-61% -$9.97M
RZLT icon
2
Rezolute
RZLT
$444M
$6.46M 38.85%
1,318,967
– –
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$1.65M 9.94%
2,823
-44
-2% -$25.9K
BRK.B icon
4
Berkshire Hathaway Class B
BRK.B
$1.06T
$514K 3.09%
1,133
-18
-2% -$8.31K
GLD icon
5
SPDR Gold Trust
GLD
$130B
$283K 1.7%
+1,169
New +$287K
DFTX
6
Definium Therapeutics
DFTX
$5.88B
$237K 1.43%
34,073
– –
BCAX
7
Bicara Therapeutics
BCAX
$1.82B
$191K 1.15%
10,941
– –
LXEO icon
8
Lexeo Therapeutics
LXEO
$368M
$117K 0.71%
17,851
– –
KYTX icon
9
Kyverna Therapeutics
KYTX
$453M
$86K 0.52%
22,981
– –
CMPX icon
10
Compass Therapeutics
CMPX
$369M
$63K 0.38%
43,465
– –
CRDF icon
11
Cardiff Oncology
CRDF
$60.2M
$57.7K 0.35%
+13,287
New +$41.5K
IKT icon
12
Inhibikase Therapeutics
IKT
$331M
$53.3K 0.32%
+16,393
New +$40.9K
CBIO
13
Crescent Biopharma
CBIO
$407M
$50.9K 0.31%
+2,036
New +$55.5K
CNTX icon
14
Context Therapeutics
CNTX
$55.1M
$19.3K 0.12%
18,403
– –
ACET icon
15
Adicet Bio
ACET
$75.9M
$16.8K 0.1%
1,093
– –
ABVX
16
Abivax
ABVX
$11.9B
– –
-11,365
Closed -$131K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q4 2024 Portfolio in Review

As of Q4 2024, Caxton Corporation held 16 positions worth $16.6M, down 31% from $24.2M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Caxton Corporation withdrew a net $9.71M in Q4 2024, closing 1 position and reducing 3 holdings. Its most notable exit was Abivax, an estimated $131K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Financials.

Against the trend, Caxton Corporation opened a new position in SPDR Gold Trust worth $283K.

  • Caxton Corporation's largest Q4 2024 buy was SPDR Gold Trust: 1,169 shares worth $283K.
  • Caxton Corporation's biggest Q4 2024 reduction was Xeris Biopharma Holdings, cutting an estimated $9.97M.
  • Caxton Corporation fully exited Abivax in Q4 2024, selling an estimated $131K.
  • Caxton Corporation's ten largest holdings make up 99% of its $16.6M portfolio in Q4 2024.
  • Caxton Corporation opened 4 new positions and closed 1 in Q4 2024.
  • Caxton Corporation's portfolio value fell 31% quarter-over-quarter to $16.6M.

Based on Caxton Corporation's 13F filing for Q4 2024, filed 14 Feb 2025.